Patients with obstructive sleep apnea who received positive airway pressure therapy had greater improvements in blood pressure compared with those who received upper airway stimulation.
Treatment response was more likely with favorable nonpharyngeal traits, moderate pharyngeal collapsibility, and weaker muscle compensation.
Interventions producing sustained weight loss of 25% to 30% of body weight recommended.
Individuals with obstructive sleep apnea who breathed through their mouths >25% of the time failed to achieve stable breathing during oronasal CPAP therapy.
The benefit of CPAP was seen for depression but not anxiety symptoms in patients with obstructive sleep apnea.
Use of continuous positive airway pressure improved obstructive sleep apnea without any changes in the neurocognitive sphere or blood pressure readings in elderly patients.
Obstructive sleep apnea and the indices of severity are heritable, while daytime sleepiness is mostly influenced by environmental factors.
A mean nocturnal respiratory rate of ≥16 breaths per minute was an independent predictor of long-term cardiovascular and all-cause mortality among community-dwelling older men and women.
The Drug Enforcement Agency (DEA) has designated Sunosi (solriamfetol; Jazz Pharmaceuticals) a Schedule IV controlled substance.
The best model for predicting obstructive sleep apnea in pregnancy incorporated BMI, age, and presence of tongue enlargement.
